Appendix E - National Coverage Determinations Manual / 220.6.4

Why This Topic Matters

This matters because colorectal cancer PET coverage is policy-driven and time-sensitive, so accurate understanding of the applicable manual language supports compliant claim submission and documentation review.

Article Sections

1. FDG PET for Colorectal Cancer (Various Effective Dates Below)

   Overview of the Medicare policy topic and the effective-date framework for the covered uses discussed in the manual entry.

2. Recurrent Colorectal Carcinoma With Rising Levels of Biochemical Tumor Marker Carcinoembryonic Antigen (CEA)

   Discussion of the earlier coverage period for recurrent colorectal cancer and the related frequency and documentation limitations.

3. Diagnosis, Staging, and Re-Staging

   Coverage guidance for diagnostic, staging, and restaging use in colorectal carcinoma, including references to associated clinical scenarios and imaging context.

4. Monitoring Response to Treatment

   Policy language addressing later coverage status for treatment-response monitoring and the evidence-development framework.

5. Requirements

   General coverage requirements for PET across diagnostic, staging/restaging, and treatment-response circumstances, along with documentation expectations.